Role of SNP Variant in FTO Explored in Obesity

This article originally appeared here.
Share this content:
Role of SNP Variant in <i>FTO</i> Explored in Obesity
Role of SNP Variant in FTO Explored in Obesity

WEDNESDAY, Aug. 19, 2015 (HealthDay News) -- A single nucleotide variant in the FTO obesity locus disrupts a conserved motif, which has obesity effects, according to a study published online Aug. 19 in the New England Journal of Medicine.

Melina Claussnitzer, Ph.D., from Harvard Medical School in Boston, and colleagues examined epigenomic data, allelic activity, motif conservation, and directed perturbations in FTO samples from patients and mice. In samples from patients, the authors performed endogenous CRISPR-Cas9 genome editing, with the aim of dissecting the regulatory circuitry and mechanistic basis of the association between the FTO region and obesity.

The researchers found that the rs1421085 T-to-C single-nucleotide variant in the FTO obesity-risk locus disrupted a conserved motif normally bound by repressor ARID5B. The disruption resulted in derepression of a potent preadipocyte enhancer, doubling expression of IRX3 and IRX5 during early adipocyte differentiation. Disruption also resulted in a cell-autonomous developmental shift from energy-dissipating beige adipocytes to energy-storing white adipocytes, with a reduction in mitochondrial thermogenesis and increase in lipid storage. Reduced body weight and increased energy dissipation were seen with inhibition of Irx3 in adipose tissue in mice. In primary adipocytes, knockdown of IRX3 or IRX5 restored thermogenesis in participants with the risk allele.

"Our results point to a pathway for adipocyte thermogenesis regulation involving ARID5B, rs1421085, IRX3, and IRX5, which, when manipulated, had pronounced pro-obesity and anti-obesity effects," the authors write.

Abstract
Full Text
Editorial

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »